Alunbrig (Brigatinib) 30mg/90mg/180mg*28's | ALK Inhibitor Japan | GLT

Generic Information: Alunbrig (Japan)

Alunbrig is the Japanese market name of brigatinib, an oral second-generation ALK inhibitor marketed by Takeda, the pharmaceutical company headquartered in Osaka, Japan. This listing covers the 30 mg, 90 mg, and 180 mg strengths, each in a 28-tablet pack. Because Takeda is a Japanese company, the Japan version is a frequently referenced reference product when buyers compare sourcing origins for the same active ingredient.

What Is Alunbrig Used For?

Alunbrig treats anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer that is locally advanced or metastatic. It is prescribed after an ALK rearrangement is confirmed by genetic testing. The drug's strong central nervous system penetration makes it a meaningful option for patients with brain metastases, a common and difficult complication of ALK+ lung cancer.

How Does Brigatinib Work?

Brigatinib is a next-generation tyrosine kinase inhibitor designed to target ALK genetic alterations. It binds ALK selectively and also inhibits ROS1, IGF-1R, and FLT-3, along with certain EGFR mutations. In the ALTA-1L study, brigatinib roughly halved the risk of disease progression or death compared with crizotinib, with a median progression-free survival of about two years, and it produced a markedly higher intracranial response rate in patients who already had brain metastases when treatment began.

Indications

Alunbrig is indicated for adults with ALK-positive, locally advanced or metastatic NSCLC. It may be used in the first-line setting or after progression on crizotinib. Confirmation of the ALK rearrangement through an approved diagnostic test is a prerequisite, as brigatinib is not effective for ALK-negative tumors.

Dosage

The recommended regimen is a 90 mg once-daily starting dose for the first week, increased to 180 mg once daily if tolerated. The tablets are taken with or without food and swallowed whole. Do not double up on a missed or vomited dose — simply resume at the next scheduled time. Any interruption of 14 days or longer calls for a 7-day 90 mg re-lead-in before returning to the higher dose.

Side Effects

Frequent side effects include diarrhea, rash, cough, hypertension, fatigue, nausea, muscle pain, shortness of breath, abdominal pain, and headache. Blood pressure should be monitored during therapy, and diarrhea generally responds to standard supportive care. Interstitial lung disease is rare but serious and requires permanent discontinuation if it develops.

Storage

Keep Alunbrig at room temperature, not exceeding 30°C, in its original packaging, protected from moisture, and away from children. No cold-chain handling is needed.

Why Choose the GLT?

GLT helps buyers source genuine, internationally approved oncology medicines with clear documentation and verified supply chains. For those comparing the Japan version against other origins of the same Takeda molecule, the Japan reference product confirms that brigatinib is the identical active ingredient wherever it is sourced, and we are ready to explain the pricing and regulatory differences between markets.

How to Order

To order Alunbrig through GLT, message us on WhatsApp at +86 15234153837 or write to [email protected]. Provide the strength, pack size, and delivery country, and our team will confirm availability, sourcing origin, and shipping terms. We work with hospitals, pharmacies, and individual patients.

FAQ

Who makes Alunbrig in Japan? Alunbrig is marketed by Takeda, which is headquartered in Osaka, Japan. The molecule was originally developed by Ariad Pharmaceuticals, which Takeda acquired.

Is brigatinib good for brain metastases? Yes. Brigatinib penetrates the blood-brain barrier well, and in the ALTA-1L trial it achieved a high intracranial response rate in patients who had brain metastases at the start of treatment.

Is Alunbrig the same everywhere? The active ingredient, brigatinib, is identical regardless of market. Packaging, labeling, and price differ by country.